Clinical Trials Browser

Turcot syndrome, Diabetes Mellitus, Insulin-Dependent, 12, Colorectal Neoplasms

NCT05571293 2026-05-22

NEST-1

Phase 2 Active not recruiting

26 enrolled 15 charts

Gastrointestinal

Diabetes Mellitus, Insulin-Dependent, 12, Colorectal Neoplasms

NCT04253080 2026-05-20

ENZYMELA

Phase NA Completed

127 enrolled

Dermatologic

Diabetes Mellitus, Insulin-Dependent, 12, Melanoma

NCT06564623 2026-05-08

Targeting Driver Oncogenes With a Peptide Vaccine Plus Durvalumab and Tremelimumab for Patients With Biliary Tract Cancers (BTC)

Phase 1 Recruiting

25 enrolled

Gastrointestinal

Diabetes Mellitus, Insulin-Dependent, 12, Biliary Tract Neoplasms, Carcinoma

NCT07354971 2026-04-28

IMMUNO-FIT Observational Study

Recruiting

67 enrolled

Diabetes Mellitus, Insulin-Dependent, 12, Neoplasms, Drug-Related Side Effects and Adverse Reactions

NCT03293784 2026-03-30

TICIMEL

Phase 1 Completed

33 enrolled

Dermatologic

Diabetes Mellitus, Insulin-Dependent, 12, Melanoma

NCT07416058 2026-02-17

PHOENIX

Phase 2 Not yet recruiting

61 enrolled

Thoracic

Diabetes Mellitus, Insulin-Dependent, 12, Adenocarcinoma of Lung

NCT07410975 2026-02-13

Efficacy of Anti-CTLA-4 Antibody Combined With Sintilimab and Chemotherapy as Neoadjuvant Therapy for Resectable Stage II-III Non-Small Cell Lung Cancer

Phase 2 Recruiting

54 enrolled

Thoracic

Diabetes Mellitus, Insulin-Dependent, 12, Carcinoma, Non-Small-Cell Lung

NCT05139706 2026-02-03

MIRAE

Recruiting

1,000 enrolled

Diabetes Mellitus, Insulin-Dependent, 12, Autoimmune Diseases, Immune System Diseases, Inflammation, Neoplasms

NCT04326257 2026-01-08

Personalized Immunotherapy in Patients With Recurrent /Metastatic SCCHN That Have Progressed on Prior Immunotherapy

Phase 2 Completed

20 enrolled 13 charts

Head & Neck

Diabetes Mellitus, Insulin-Dependent, 12, Squamous Cell Carcinoma of Head and Neck, Neoplasm Metastasis, Recurrence

NCT07243951 2025-11-24

Phase II Clinical Study on the Efficacy and Safety of the Combination of Cadonilimab and Capecitabine in Adjuvant Therapy for Combined Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma

Phase 2 Not yet recruiting

75 enrolled

Gastrointestinal

Diabetes Mellitus, Insulin-Dependent, 12, Liver Neoplasms

NCT03911557 2025-11-12

Durvalumab and Tremelimumab Combination in Somatically Hypermutated Recurrent Solid Tumors

Phase 2 Completed

14 enrolled

Diabetes Mellitus, Insulin-Dependent, 12, Neoplasms

NCT07131501 2025-08-20

A Single-Arm, Multicenter, Exploratory Clinical Study of TACE Combined With Iparomlimab and Tuvonralimab Injection (QL1706) and Lenvatinib for Perioperative Treatment of Resectable Hepatocellular Carcinoma

Phase 2 Not yet recruiting

48 enrolled

Gastrointestinal

Diabetes Mellitus, Insulin-Dependent, 12, Carcinoma, Hepatocellular

NCT03638141 2025-08-17

CTLA-4 /PD-L1 Blockade Following Transarterial Chemoembolization (DEB-TACE) in Patients With Intermediate Stage of HCC (Hepatocellular Carcinoma) Using Durvalumab and Tremelimumab

Phase 2 Completed

21 enrolled 12 charts

Gastrointestinal

Diabetes Mellitus, Insulin-Dependent, 12, Carcinoma, Hepatocellular

Clinical Trials

Cadonilimab for PD-1/PD-L1 Blockade-refractory, MSI-H/dMMR, Advanced Colorectal Cancer

NEST-1

ENZYMELA

Targeting Driver Oncogenes With a Peptide Vaccine Plus Durvalumab and Tremelimumab for Patients With Biliary Tract Cancers (BTC)

IMMUNO-FIT Observational Study

TICIMEL

PHOENIX

Efficacy of Anti-CTLA-4 Antibody Combined With Sintilimab and Chemotherapy as Neoadjuvant Therapy for Resectable Stage II-III Non-Small Cell Lung Cancer

MIRAE

Personalized Immunotherapy in Patients With Recurrent /Metastatic SCCHN That Have Progressed on Prior Immunotherapy

Phase II Clinical Study on the Efficacy and Safety of the Combination of Cadonilimab and Capecitabine in Adjuvant Therapy for Combined Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma

Durvalumab and Tremelimumab Combination in Somatically Hypermutated Recurrent Solid Tumors

A Single-Arm, Multicenter, Exploratory Clinical Study of TACE Combined With Iparomlimab and Tuvonralimab Injection (QL1706) and Lenvatinib for Perioperative Treatment of Resectable Hepatocellular Carcinoma

CTLA-4 /PD-L1 Blockade Following Transarterial Chemoembolization (DEB-TACE) in Patients With Intermediate Stage of HCC (Hepatocellular Carcinoma) Using Durvalumab and Tremelimumab